venture fund, Lilly and Andreessen Horowitz

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with ...
Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...
Though we’re well into the winter season, Lilly Pulitzer always finds a way to get us excited for spring and summer. The ...
Forty submissions, weeks of polls and several thousand votes from Herald-Leader subscribers have finally brought us to this ...
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...